The Honest Dose #13

I've spent the last several weeks making video content, which means I've spent the last several weeks actually watching it.

That turns out to be a different experience than reading about this space. Scrolling short-form video is a different world, and what's struck me is not that there's misinformation in it, I expected that, but how consistent the direction of the misinformation is. The confident claims cluster almost entirely around the compounds with the least evidence behind them.

Here's what makes that strange. There is no shortage of genuinely well-studied material in this space. There are peptides and peptide-adjacent compounds with real clinical trial programs, decades of safety data, approvals in dozens of countries, and legitimate paths to access through a doctor and a licensed pharmacy. Those compounds exist. They are interesting. Almost nobody is making videos about them.

Instead, the energy goes to the newest, least-characterized, hardest-to-source options. And that pattern raises a question I don't think has a comfortable answer: is that because those compounds are genuinely more transformative, or is it because the ones you can't get through normal channels are the ones with the most room for margin? A compound available by prescription from a regulated pharmacy has a price, a supply chain, and oversight. A compound sold as a research chemical from an unregulated seller has none of those things, which means far more room for markup, for affiliate arrangements, and for claims nobody has to substantiate. I genuinely don't know how much of the pattern is real enthusiasm and how much is incentive. Probably a mix. But you can't look at it honestly and conclude that incentive plays no part.

There's a companion argument I keep running into, and it deserves a straight response. When someone points out a compound isn't FDA-regulated, the reply is often a list of things the FDA has approved that people consider harmful. I understand the frustration underneath it. But it's answering a question nobody asked. FDA approval is a narrow claim: that a specific product, for a specific use, cleared a specific evidence review. It was never a blanket statement that a substance is good for you, and pointing at an unrelated approval tells you exactly nothing about whether the compound in front of you has been studied. Whatever you think of the agency, "they approved something else I disagree with" is not evidence about this compound. It changes the subject.

My position on all of this is simple and I want to state it plainly. I think adults have the right to research and experiment with whatever compounds they choose. That is not my call to make and I have no interest in gatekeeping it. What I care about is that the information people use to make that decision arrives undiluted, not filtered through somebody's margin. That's the entire reason the Research Quality Score exists. It lays the evidence bare and lets you decide, whatever you decide.

But the evidence behind a compound is only half of what determines your outcome. The other half is who you buy from. So today I'm launching the second framework.

Let's get into it.

The Vendor Transparency Score grades a vendor on how openly and verifiably they document their process, using only signals a stranger can confirm from public materials. It's a 7-dimension, 100-point framework, the same architecture as the RQS, aimed at an entirely different target. RQS measures the quality of the research behind a compound. VTS measures whether a vendor's process claims can actually be checked.

It's live now at peptideclear.com/vts-methodology, alongside the RQS under a shared methodology hub.

This is the part I need to be unambiguous about, because it's the part most likely to be misread.

VTS measures whether a vendor's process claims are documented, current, lot-matched, and independently verifiable from their own public materials. Transparency in the literal sense: can an outsider check the work.

VTS does not measure product safety, purity, potency, or efficacy. It does not tell you whether a compound works or is safe to use. It does not certify anyone as legitimate or approved. A vendor can score High on transparency and still sell something you should not put in your body. Transparency is not endorsement, and I'd rather say that too many times than not enough.

Testing practice carries the most weight because it's the single most predictive signal of whether a vial matches its label. Everything else is downstream of whether anyone independent ever looked.

Bands run High Transparency (80-100), Moderate (60-79), Limited (40-59), Low (20-39), and Opaque (0-19). Those labels are deliberately different from the RQS bands, so that a vendor scoring 85 is never mentally filed next to a compound scoring 85. They are not the same kind of number and I didn't want the interface to imply otherwise.

Three design decisions matter more than the rubric itself.

Vendors are scored whether or not they want to be. A low score for opacity is a valid, publishable result. The moment a roster is limited to vendors who opted in, or who look good, or who paid, the score stops being measurement and becomes marketing. That failure mode is common enough in this space that avoiding it was a founding constraint, not an afterthought.

Every scored point links to the specific public page, COA, or record it came from. If a vendor disputes a result, the evidence is their own published material. Nothing in a score rests on my impression of anyone.

Community experience sits beside the score, never inside it. Real-world reports are informative but they aren't verifiable on the same terms as a published document, and letting sentiment move the number would corrupt the thing that makes it worth reading. So Community Signal is its own labeled field, split into two streams: independent test results, where someone bought product themselves and sent it to a lab, which is arguably more objective than a vendor-selected sample, and general community experience on reship and refund behavior. Both inform the write-up. Neither touches the seven-dimension score.

There's also a Viability Flag that can cap a band regardless of documentation, triggered when there's public evidence an operation may be defunct. Perfect paperwork means nothing if the vendor no longer exists.

PeptideClear has no affiliate, referral, or commercial relationship with any scored vendor. Vendor links exist for source attribution, so you can check the same page I checked. Clicking one generates no revenue here. A vendor appearing in the log is not an endorsement, and a high score is not a recommendation to buy.

I'm aware that's an unusual thing to build. A vendor scoring system with affiliate links attached would be considerably more profitable and considerably less useful, and you would be right to discount every number in it. The score is only worth reading if I have nothing riding on the result.

The log launches with nine vendors scored, spanning the range from High Transparency down to Low. I'm not naming or ranking them here, because a newsletter blurb strips away the per-dimension reasoning that makes a score meaningful, and the whole point is that you can audit the work rather than take my word for it. The full log, with every dimension broken out and every source linked, is on the methodology page.

New vendors get added over time. If there's one you're trying to evaluate, reply to this email and tell me, because the score is most useful where people are already trying to make a decision.

View the VTS methodology and vendor log

The claim: Canola, soybean, sunflower, corn, and similar oils are industrially processed inflammatory toxins driving the chronic disease epidemic. Cut them out and inflammation drops, energy returns, and a long list of complaints resolves. This is one of the largest wellness narratives on the internet right now, with restaurant chains advertising their absence and an entire product category built on avoiding them.

The reality: The underlying mechanism sounds genuinely plausible, which is what makes it durable. Seed oils are high in linoleic acid, an omega-6 fatty acid. Linoleic acid can be converted into arachidonic acid, which is a precursor to inflammatory signaling molecules. So the chain of reasoning is: more seed oil, more linoleic acid, more arachidonic acid, more inflammation. Every link exists in a biochemistry textbook.

The problem is that the pathway barely runs in humans. Only around 0.2 percent of dietary linoleic acid actually gets converted to arachidonic acid, because the enzymatic step is tightly regulated. Eating more linoleic acid does not meaningfully raise tissue arachidonic acid levels, which means the mechanism that the entire theory depends on doesn't behave the way the theory needs it to.

And when researchers went and measured it directly, the results went the other way. A systematic review pooling 30 randomized controlled trials found that increasing dietary linoleic acid did not raise inflammatory markers. A separate review of 15 RCTs in healthy adults found no significant effect on CRP, TNF-alpha, or the other standard inflammation measures. A 2024 meta-analysis found higher linoleic acid intake correlated with lower CRP and IL-6. Pooled cohort data covering tens of thousands of people links higher linoleic acid to lower cardiovascular risk and lower mortality. Major bodies including the American Heart Association and WHO have looked at this and concluded there's no reason to avoid these oils.

Now the honesty requirement, because this is a case where I have to apply my own rules to myself. A good deal of the pro-seed-oil material circulating right now comes from industry-affiliated organizations, and one of the most-cited recent reviews was published through a seed oil industry body. That's a Funding Independence problem and I'm not going to pretend it isn't. What saves the conclusion here is that the independent evidence stands on its own: the Cochrane-style RCT reviews, the academic pooled cohort analyses, and the public health guidance don't depend on industry-funded work to reach the same place. When the industry-funded and the independently-funded literature agree, the funding problem gets much smaller. It's worth noticing, and it isn't disqualifying here.

One real caveat: none of this makes any food containing seed oil healthy. Most seed oil in the American diet arrives inside ultra-processed food that is also high in refined starch, sodium, sugar, and calories. Those foods are worth eating less of. But the evidence points at the food, not the oil, and swapping the fryer oil in an ultra-processed product doesn't fix what's actually wrong with it.

The honest version of the claim: The inflammation mechanism is biochemically real and physiologically negligible, and controlled human trials consistently fail to find the effect the theory predicts. Seed oils are not poisoning you. The processed food they usually arrive in is a legitimate thing to eat less of, and that distinction is doing all of the work the seed oil narrative takes credit for.

I want to use this space to explain why there are now two frameworks instead of one, because the reason goes directly to the thing I opened with.

The RQS answers one question: how much methodological weight can the published human evidence behind this compound bear. That question is necessary and it is not sufficient, because a perfect score tells you nothing about the vial that arrives at your door. A compound can have a strong research base and reach you as something mislabeled, underdosed, or not the compound at all. The research grade and the sourcing grade are independent variables, and confusing them is one of the most common failure modes in this space.

The two frameworks share one discipline, and it's the thing I'd want understood about both: publish the grade, never endorse. Both score on verifiable inputs only. Neither renders a verdict on safety or efficacy. Both live or die on whether an outsider can reproduce the reasoning.

They also share a structural insight worth naming. The RQS dedicates a full dimension to Funding Independence because who paid for research, and who stood to benefit from its outcome, changes how you should read the result. The VTS is that same instinct pointed at commerce. When a seller writes the claim and also collects the money, you need to know whether anyone independent ever checked. That's why Third-Party Testing Practice carries 30 of the 100 points. Independent verification is the whole ballgame, in a lab and in a literature.

And it's why the seed oil piece above needed that funding paragraph. The rule doesn't get suspended when a well-funded literature happens to support the conclusion I'd have reached anyway. Applying it only when it's convenient would make it decoration rather than method.

Louisiana's peptide law took effect August 1.
Senate Bill 253 is now in force, adding a new section to Louisiana law that bars professional and occupational licensing boards from prohibiting a healthcare provider with prescriptive authority from providing patients peptides, provided those peptides ship from an FDA-registered 503B outsourcing facility or a 503A compounding pharmacy that sources its active ingredients from an FDA-registered manufacturer. The provider must also confirm the peptide isn't on the FDA's prohibited compounding list. It's worth being precise about what this is: not a legalization, and not a change to what may be compounded. It's a restriction on state licensing boards, protecting prescribers from board discipline for working within the existing federal compounding framework. The interesting part is the direction of travel, with a state legislating to keep this pathway open while the federal picture is still being worked out. I'll be watching whether other states follow this template.

Watch what the PCAC vote does to vendor marketing.
I flagged this last issue and it's the reason the VTS launched now rather than later. Following July's advisory recommendations, expect "FDA approved," "FDA cleared," and "now legal" to start appearing on product pages for the six recommended compounds. All of those remain false today. The vote was advisory, rulemaking hasn't happened, and a 503A listing would not be a drug approval even if it completes. A vendor making that leap is telling you something about how they handle claims generally, which is exactly the kind of signal worth weighing.

The compounds nobody is making videos about.
Coming out of a month of consuming content in this space, the thing I keep noticing is the inverse relationship between how well-studied a compound is and how much promotional energy surrounds it. I'm going to start deliberately covering the other end of that curve, because the well-evidenced material genuinely is more interesting than it gets credit for. Starting with the one below.

Sermorelin is the clearest example in the whole catalog of the pattern I described up top: a better-evidenced, legally accessible option sitting quietly next to far more popular alternatives with far thinner research.

It's a synthetic analog of the body's own growth hormone releasing hormone, made of its first 29 amino acids. It works by stimulating the pituitary to produce growth hormone through the normal physiological pathway, rather than supplying growth hormone directly. What makes it unusual here is its regulatory history: it's the only peptide in the catalog with prior FDA approval, previously prescribed for pediatric growth hormone deficiency. It remains available today by prescription through licensed compounding pharmacies. A doctor, a pharmacy, a known supply chain.

Now the comparison. Sermorelin scores 64, in the Moderate band. The two compounds most commonly discussed in the same context, Ipamorelin and CJC-1295, score 35 and 44 respectively, both well below it, and neither has Sermorelin's approval history or its prescription pathway. The most popular option in this category by community volume is not the best-evidenced one, and it isn't close.

I want to be careful not to overclaim in the other direction. A 64 is Moderate, not Strong. It means human evidence exists but is limited in scale, replication, or rigor, and much of Sermorelin's clinical record comes from a specific pediatric deficiency indication rather than the adult longevity and performance uses that drive most current interest. That gap between the approved indication and the popular use is real and worth holding onto. It scores where it scores.

But that's the point. A compound with an actual approval history, a legal prescription route, and a Moderate evidence grade generates a fraction of the enthusiasm of research chemicals scoring in the thirties. Whatever explains that, it isn't the strength of the research.

RQS: 64/100 - Moderate Evidence

Read the full Sermorelin profile

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.